cmpd a

MS 347a is a myosin light chain kinase (MLCK) inhibitor; an epoxide analog of sydowinin B (MS-347b).

Cmpd-A is a time-dependent CENP-E inhibitor with potent antitumor activity. Cmpd-A inhibits the ATPase activity of the CENP-E motor domain, acting as a time-dependent inhibitor with an ATP-competitive-like behavior. Cmpd-A causes chromosome misalignment on the metaphase plate, leading to prolonged mitotic arrest. Treatment with Cmpd-A induces antiproliferation in multiple cancer cell lines.

CMPDA is a positive allosteric modulator of AMPA receptors [EC50s: 45.4 nM/63.4 nM for GluA2i/GluA2o receptor].

Cmpd 339509 is a DprE1 inhibitor. DprE1 is an epimerase required for cell wall biosynthesis.

(R)-CMPD-39 is the R-enantiomer of CMPD-39. CMPD-39 acts as a selective non-covalent inhibitor of the ubiquitin-specific protease USP30 with an IC50 of approximately 20 nM and demonstrates high selectivity for other DUB family members at concentrations ranging from 1-100 μM. By inhibiting USP30's deubiquitination activity, CMPD-39 enhances the ubiquitination of mitochondrial proteins TOMM20 and SYNJ2BP and promotes the accumulation of phosphorylated ubiquitin. This process accelerates both mitophagy and pexophagy. Additionally, CMPD-39 significantly restores impaired mitochondrial function in dopaminergic neurons derived from Parkinson’s disease patients.

CMPD1 is a non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor(apparent Ki (Kiapp): 330 nM).

CMPD101 is a membrane-permeable small-molecule inhibitor of GRK2/3 (IC50: 18 nM and 5.4 nM). Which can be used for the study of heart failure. CMPD101 exhibits less selectively against GRK1, GRK5, ROCK-2 and PKCα with IC50s of 3.1 μM , 2.3 μM, 1.4 μM and 8.1 μM, respectively.

CMPD167 (MRK-1) is a potent, orally active inhibitor of CCR5 with significant in vitro antiviral efficacy [1].

CMPD101 hydrochloride is a membrane-permeable small molecule inhibitor of GRK2 and GRK3, exhibiting IC50 values of 18 nM and 5.4 nM, respectively. This compound also inhibits Rho-associated kinase 2 (ROCK-2) and PKCα, with IC50 values of 1.4 μM and 8.1 μM, respectively.

BI-671800 (AP-761) is a highly specific and potent antagonist of chemoattractant receptor-homologous molecule on Th2 cells (DP2/CRTH2). With IC50 values of 4.5 nM and 3.7 nM for PGD2 binding to CRTH2 in hCRTH2 and mCRTH2 transfected cells, respectively. BI-671800 has the potential to treat poorly controlled asthma[2].

Takeda103A (CMPD103A) is the GRK2-dependent bovine tubulin oxidation effective inhibitor.